Invion is developing the Photosoft™ technology for the treatment of cancers and infectious diseases and atherosclerosis (AID).
The Company’s priority during the quarter is to work with its partners, including the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, to complete the preparatory groundwork for the upcoming clinical trials. The drug discovery work on both topical and intravenous (IV) formulations of INV043, the lead drug candidate, have been completed.
Meanwhile, Invion and its partners have made significant progress on the pre-clinical studies required for the Phase 1trials, including having largely completed this work for the topical drug product, which will be used in the skin cancer and anogenital cancer trials.
The Company is progressing on the pre-clinical studies for the IV drug product that will be used in future solid tumour clinical trials.
Further, Invion is working with IDT Australia Limited (ASX: IDT) on manufacturing the Active Pharmaceutical Ingredient (API) drug substance, and is also working on manufacturing drug products for both topical and IV administrations.
Additionally, drug discovery studies using Photosoft on infectious diseases and atherosclerosis are continuing with research partners including the Australian Centre for Antimicrobial Resistance Ecology (ACARE), which is part of the University of Adelaide. Invion will release further results from these studies as they become available.
IVX Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)